Masimo Corp. in Irvine received FDA clearance for the sale of its TFA-1 Single-Patient-Use Adhesive Forehead Sensor.
The forehead sensor measures oxygen saturation, similar to the company’s current products, but the company said the new indication provides an alternative monitoring site to a patient’s finger, allowing faster detection and easier access during surgery.
The single-use device is likely also to be promoted as avoiding the need for cleaning, storage and inter-department transport of reusable sensors.
Masimo makes and markets noninvasive patient monitoring devices.
It traded recently at about a $3.4 billion market cap.